Barriers to Lactulose Adherence in Patients with Cirrhosis and Hepatic Encephalopathy

Dig Dis Sci. 2023 Jun;68(6):2389-2397. doi: 10.1007/s10620-023-07935-z. Epub 2023 Apr 29.

Abstract

Background: Hepatic encephalopathy (HE) is a major cause of mortality and morbidity in patients with cirrhosis. Lactulose non-adherence is one of the most frequently reported precipitants of hospital admission for HE.

Aims: We aimed to identify which factors contribute most to lactulose non-adherence and propose strategies to promote greater adherence and utilization of lactulose.

Methods: Participants in this study consisted of patients with cirrhosis who were taking lactulose for prevention of HE. Subjects were administered the Morisky Adherence Scale 8 (MAS-8) and a customized 16-question survey that assessed barriers to lactulose adherence. Results from the MAS-8 were used to stratify subjects into "adherent" and "non-adherent" groups. Survey responses were compared between groups.

Results: We enrolled 129 patients in our study, of whom 45 were categorized as "adherent and 72 were categorized as "non-adherent." Barriers to adherence included large volumes of lactulose, high frequency of dosing, difficulty remembering to take the medication, unpleasant taste, and medication side-effects. Most patients (97%) expressed understanding of the importance of lactulose, and 71% of patients felt that lactulose was working to manage their HE. Hospital admission rates for HE was higher in non-adherent patients, although this difference was not statistically significant.

Conclusion: We identified several factors that contribute to lactulose non-adherence among patients treated for HE. Many of these factors are potentially modifiable. Patient and care-giver education are critical to assure adherence. Pharmacists and nurses are an essential but underutilized aspect of education regarding proper medication use.

Keywords: Adherence; Encephalopathy; Hepatic; Lactulose.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Gastrointestinal Agents / adverse effects
  • Hepatic Encephalopathy* / drug therapy
  • Hepatic Encephalopathy* / etiology
  • Hepatic Encephalopathy* / prevention & control
  • Hospitalization
  • Humans
  • Lactulose* / therapeutic use
  • Liver Cirrhosis / chemically induced
  • Liver Cirrhosis / complications
  • Liver Cirrhosis / drug therapy

Substances

  • Lactulose
  • Gastrointestinal Agents